Dechra Pharmaceuticals yesterday reported a rise in pre-tax profit for its recently ended financial year.
For the year to 30 June, the veterinary pharmaceutical business posted a pre-tax profit of £25.8m, up from £21.4m a year before. This came on a 5.1 per cent rise in revenue to £203.5m from £193.6m.
“The board believes that our focus on our key therapy areas, the continued rate of adoption of Osphos and sales in our new territories will drive progress in the short term,” said chairman Michael Redmond.
“In the long-term, the delivery of further new products and the integration of potential acquisitions give the board confidence in the group’s future prospects.”